
    
      This is a multicenter, prospective, open-label study to determine the efficacy and safety of
      andexanet in patients who require urgent surgery who have received 1 of the following FXa
      inhibitors: apixaban, rivaroxaban, edoxaban, or enoxaparin. The start of surgery must be
      within 15 hours following the last dose of FXa inhibitor. The primary efficacy outcome will
      be adjudicated by an independent Endpoint Adjudication Committee.
    
  